Lifecore Biomedical Signs New Agreement with Global Pharmaceutical Company
Rhea-AI Summary
Lifecore Biomedical (NASDAQ: LFCR) signed a new agreement with a global pharmaceutical company to provide tech transfer and commercial manufacturing services for an injectable suspension product treating neurological disorders.
This becomes Lifecore’s seventh late-stage program agreement in seven months, underscoring growing demand for its high-viscosity and complex drug manufacturing capabilities in the U.S.
Positive
- Seventh late-stage program agreement secured within seven months
- New agreement for commercial manufacturing of neurology injectable suspension
- Validates Lifecore’s expertise in high-viscosity and complex formulations
- Enhances positioning as U.S.-based CDMO partner for multinational pharma
Negative
- None.
News Market Reaction – LFCR
In the Jun 15 session, LFCR declined 2.66%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | New CDMO agreement | Positive | +12.4% | Signed manufacturing and tech transfer deal for next-gen ophthalmic injectable. |
| May 21 | Conference participation | Positive | +9.0% | Announced participation and investor meetings at William Blair growth conference. |
| May 06 | Q1 2026 earnings | Negative | -3.9% | Reported revenue decline, net loss, but reaffirmed full-year guidance. |
| Apr 29 | Earnings date notice | Neutral | +2.6% | Set date and webcast details for upcoming Q1 2026 results release. |
| Apr 22 | Equity inducement grant | Neutral | -5.9% | Granted 5,000 RSUs to a new employee under equity inducement plan. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent commercial and investor-relations news has often coincided with positive price reactions, while governance and compensation items drew a weaker or negative response.
Over the last few months, Lifecore has expanded its CDMO pipeline and engaged investors. A June 2, 2026 manufacturing agreement for an ophthalmic injectable lifted shares by 12.37%, adding a sixth late-stage program in seven months. Participation in a major growth conference on May 21, 2026 saw an 8.97% gain. By contrast, Q1 2026 results on May 6 with revenues of $23.2M (-34% YoY) led to a -3.88% move. Today’s new neurology-focused agreement extends this late-stage portfolio build-out trend.
Key Terms
contract development and manufacturing organization technical
cdmo technical
technical transfer services technical
injectable suspension product medical
neurological disorders medical
high-viscosity technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
--Agreement Supports Tech Transfer and Commercial Manufacturing of Currently Marketed Neurology Product--
--Seventh Addition to Lifecore’s Late-Stage Pipeline in Seven Months--
CHASKA, Minn., June 15, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced it has signed a new agreement with a global pharmaceutical company. Under the terms of the agreement, Lifecore will perform technical transfer services to support the commercial production of an injectable suspension product for neurological disorders.
“With this significant new customer win, we have secured our seventh agreement for a late-stage program within the last seven months, reflecting how our focused business development efforts have created strong momentum and results for continued portfolio growth,” said Paul Josephs, chief executive officer of Lifecore. “Being selected to produce this higher-viscosity suspension formulation demonstrates confidence in Lifecore’s technical know-how and exceptional quality track record.
“This opportunity also highlights the increasing demand for specialized manufacturing expertise to produce high-viscosity and other complex pharmaceutical products. Lifecore’s unique capabilities position us as a valuable partner, able to address the diverse needs of multinational pharmaceutical companies seeking to leverage manufacturing operations in the U.S.”
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements regarding future events and our future results that are subject to the safe harbor created under the Private Securities Litigation Reform Act of 1995 and other safe harbors under the Securities Act of 1933 and the Securities Exchange Act of 1934. Words such as “anticipate”, “estimate”, “expect”, “project”, “aim,” “designed to,” “plan”, “intend”, “believe”, “may”, “might”, “will”, “should”, “can have”, “likely” and similar expressions are used to identify forward-looking statements. In addition, all statements regarding our future financial and operating performance and strategy, including our strong momentum and results for continued portfolio growth; the increasing demand for specialized manufacturing expertise to produce high-viscosity and other complex pharmaceutical products; and our position as a valuable partner, able to address the diverse needs of multinational pharmaceutical companies seeking to leverage manufacturing operations in the U.S., are forward-looking statements. All forward-looking statements involve certain risks and uncertainties that could cause actual results to differ materially, including such factors as, among others, the timing and amount of future expenses, revenue, net income (loss), Adjusted EBITDA, cash flow and capital requirements, and timing and availability of and the need for additional financing; our ability to maintain or expand our relationships with our current customers, including the impact of changes in consumer demand for the products we manufacture for our customers; our ability to grow and diversify our business with new customers, including the potential loss of development customers if they do not receive required funding or regulatory approvals or for other reasons; our ability to comply with covenants under our credit agreements and to pay required interest and principal payments when due; our ability to fund any redemptions of shares of the outstanding Series A Convertible Preferred Stock if requested by holders in accordance with their terms; our ability to raise additional capital for ongoing needs, including through equity financing, debt financing, collaborations, strategic alliances or licensing arrangements; the impact of macroeconomic events or circumstances on our operations and financial performance, including inflation, tariffs, interest rates, social unrest and global instability; the performance of our third-party suppliers; pharmaceutical industry market forces that may impact our customers’ success and continued demand for the products we produce for those customers; our ability to recruit or retain key scientific, technical, business development, and management personnel and our executive officers; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including current Good Manufacturing Practice, or cGMP; the outcome and cost of existing and any new litigation or regulatory proceedings; and other risk factors set forth from time to time in the company’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-KT for the transition period ended December 31, 2025 (the “December 2025 10-KT”). For additional information about factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to our filings with the SEC, including the risk factors contained in the December 2025 10-KT. Forward-looking statements represent management’s current expectations as of the date hereof and are inherently uncertain. Except as required by law, we do not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.
Contact Information:
Vida Strategic Partners
Stephanie Diaz (Investors)
415-675-7401
sdiaz@vidasp.com
Jennifer Arcure (Media)
917-603-0681
jarcure@vidasp.com
Lifecore Biomedical
Ryan D. Lake (CFO)
952-368-6244
ryan.lake@lifecore.com
